Assessment of efficacy and prognostic factors by Gelfoam for DEB-TACE in unresectable large hepatocellular carcinoma with portal vein tumor thrombus: a multi-center retrospective study

References

• Peng SY, Wang XA, Huang CY, et al. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol. 2018;24(40):4527–4535.
   PubMed Web of Science ®Google Scholar
• Liang L, Chen TH, Li C, et al. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford). 2018;20(12):1119–1129.
   PubMed Web of Science ®Google Scholar
• Cheng SQ, Yang JM, Shen F, et al. Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - eastern hepatobiliary surgical hospital consensus statement. Oncotarget. 2016;7(26):40816–40829.
   PubMedGoogle Scholar
• Cheng SQ, Chen MS, Cai JQ, National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumor Thrombus. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget. 2017;8(5):8867–8876.
   PubMedGoogle Scholar
• Zhang XP, Wang K, Wang M, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget. 2017;8(17):29416–29427.
   PubMedGoogle Scholar
• Yau T, Tang VY, Yao TJ, et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(e1693):1691–1700.
   PubMedGoogle Scholar
• Silva JP, Berger NG, Tsai S, et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford). 2017;19(8):659–666.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang YW, Guo Z. Clinical experience of GSPs-TACE in treatment of hepatocellular carcinoma with blood-rich portal carcinoma[J]. Natl Med J China. 2014;94(7):549–550.
   Google Scholar
• Tovoli F, Renzulli M, Negrini G, et al. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. Eur Radiol. 2018;28(9):3611–3620.
   PubMed Web of Science ®Google Scholar
• Sereni CP, Rodgers SK, Kirby CL, et al. Portal vein thrombus and infiltrative HCC: a pictoral review. Abdom Radiol (NY). 2017;42(1):159–170.
   PubMed Web of Science ®Google Scholar
• Al-Azzawi Y, Rouanet E, Hendrix RJ, et al. Segmental distribution of hepatocellular carcinoma correlates with microvascular invasion in liver explants undergoing transplantation. J Cancer Epidemiol. 2019;2019:8534372.
   PubMed Web of Science ®Google Scholar
• Jang TY, Huang CI, Yeh ML, et al. The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. Medicine (Baltimore). 2019;98(13):e15066.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zou R, Zheng Y, et al. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation. Eur Radiol. 2019;29(11):5752–5762.
   PubMed Web of Science ®Google Scholar
• Yang B, Li CL, Guo WH, et al. Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus. BMC Cancer. 2018;18(1):101.
   PubMedGoogle Scholar
• Zou JW, Zhu WL, Meng H, et al. Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2019;13(3):271–279.
   PubMed Web of Science ®Google Scholar
• Yuan J, Yin X, Tang B, et al. Transarterial chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Biomed Res Int. 2019;2019:2141859.
   PubMed Web of Science ®Google Scholar
• Fan W, Yuan G, Fan H, et al. Apatinib combined with transarterial chemoembolization in patients with hepatocellular carcinoma and portal vein tumor thrombus: a multicenter retrospective study. Clin Ther. 2019;41(8):1463–1476.
   PubMed Web of Science ®Google Scholar
• Shui Y, Yu W, Ren X, et al. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with Extensive portal vein tumor thrombosis. Radiat Oncol. 2018;13(1):188.
   PubMedGoogle Scholar
• Somma F, Stoia V, Serra N, et al. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: the impact of portal vein thrombosis on survival. PLoS One. 2019;14(5):e0216935.
   PubMed Web of Science ®Google Scholar
• Wang W, Shen J, Wang C, et al. Safety and feasibility of helical I-125 seed implants combined with transcatheter arterial chemoembolization in hepatocellular carcinomas with main portal vein tumor thrombus. Cardiovasc Intervent Radiol. 2019;42(10):1420–1428.
   PubMed Web of Science ®Google Scholar
• Farid K, Elalfy H, Abo El-Khair SM, et al. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. Expert Rev Gastroenterol Hepatol. 2020;14(12):1203–1214.
   PubMed Web of Science ®Google Scholar
• Liu YS, Lin CY, Chuang MT, et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol. 2018;18(1):124.
   PubMedGoogle Scholar
• Gorodetski B, Chapiro J, Schernthaner R, et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol. 2017;27(2):526–535.
   PubMed Web of Science ®Google Scholar
• Zhang YW, Ao J, Liu Y, et al. Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization[J]. Tumour Biol. 2014;35(11):10905–10910.
   PubMedGoogle Scholar
• Liu Y, Zhang YW, Bautista D, et al. Trans-arterial p53-Gene-Embolization with gelatin sponge microparticles for hepatocellular carcinoma with BCLC stage B: single-center experience. Cell Biochem Biophys. 2015;71(1):99–104.
   PubMed Web of Science ®Google Scholar
• Wu PZ, Zhou J, Zhang YW. Gelatin sponge microparticles for the treatment of spontaneous rupture of hepatocellular carcinoma hemorrhage[J]. Exp Ther Med. 2016;12(4):2201–2207.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wang Z, Zhao GS, et al. Experimental study on embolization of rabbit renal artery with gelatin sponge microspheres. J Can Res Ther. 2020;16:1617–1624.
   PubMed Web of Science ®Google Scholar
• Ren ZZ, Yue YX, Zhang YW, et al. Changes in the peripheral blood treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles. Front Immunol. 2021;12:624789.
   PubMed Web of Science ®Google Scholar
• Cerban R, Ester C, Iacob S, et al. Predictive factors of tumor recurrence and survival in patients with hepatocellular carcinoma treated with transarterial chemoembolization. J Gastrointestin Liver Dis. 2018;27(4):409–417.
   PubMed Web of Science ®Google Scholar
• Akkiz H, Carr BI, Kuran S, et al. Macroscopic portal vein thrombosis in HCC patients. Can J Gastroenterol Hepatol. 2018;2018:3120185.
   PubMed Web of Science ®Google Scholar
• Abdelmaksoud AH, Mandooh S, Nabeel MM, et al. Portal vein thrombosis in unresectable hcc cases: a single center study of prognostic factors and management in 140 patients. Asian Pac J Cancer Prev. 2017;18(1):183–188.
   PubMedGoogle Scholar